HealthEquity, Inc. (HQY) fair value analysis
Nasdaq · Updated 2026-10-19
HQY price how computed
Forward Fair Value verdict
UndervaluedHQY is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $92.03
- Sector
- Healthcare
- 12-month range
- $73.21–$106.79
- Market cap
- $7.61B
- From 52-week high
- -13.8%
- Shares outstanding
- 82.7M
- Rank in Healthcare by discount to fair value
- #10 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
HealthEquity, Inc. is a healthcare technology company that provides cloud-based platforms and services for health savings accounts, flexible spending accounts, and other consumer-directed benefits. The company operates in the United States, serving employers, health plans, and individual consumers through its digital ecosystem.
HQY currently ranks #10 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $7.61B
- P/E (trailing)
- 23x
- Revenue (TTM)
- $1.36B
- Net margin
- 17.4%
- EPS (TTM)
- $4.07
- Gross margin
- 73.5%
- Debt / equity
- 0.49
- Revenue growth (3-yr avg)
- 13.6%
- Shares outstanding
- 82.7M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 46 · neutral
- 50-day average
- $96.25
- 200-day average
- $88.58
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-12-02
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-07 ▲ beat (+5.1%)
2026-04 ▲ beat (+13.8%)
2026-01 ▲ beat (+5.8%)
2025-10 ▲ beat (+11.0%)
2025-07 ▲ beat (+17.4%)
2025-04 ▲ beat (+19.8%)
2025-01 ▼ miss (-4.2%)
2024-10 ▲ beat (+8.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 15 buy · 0 hold · 0 sell (15 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $119
- Target vs last price
- +29.3%
What our data shows for HQY
- Our model validated 17 trailing price-to-earnings windows for HQY, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $73.21–$106.79.
- The 14-day relative strength index sits at a neutral 46.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for HQY
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent HQY news
TickrTrends' derived news-sentiment signal for HQY is currently leaning positive, computed from recent coverage.
- HQY Maintained by BMO Capital -- Price Target Raised to $125 (gurufocus.com, 2026-10-21)
TickrTrends take: BMO Capital's maintenance of coverage with a raised price target to $125 suggests analyst confidence in HQY's fundamentals within the Healthcare sector. Given TickrTrends' current assessment of the stock as undervalued, this price target elevation provides a data point for valuation-focused readers to monitor against the company's actual trading price and near-term financial performance. Investors tracking the gap between the new analyst target and the stock's market price may gain insight into how the market is pricing in the company's growth prospects relative to the analyst's view. - A Look at HealthEquity Inc (HQY) After 3.8% Gain -- GF Value $107.81 vs Price $96.60 (gurufocus.com, 2026-10-20)
TickrTrends take: HealthEquity Inc trades at a discount to its GF Value estimate, with the stock currently priced below the fundamental valuation benchmark. The recent gain provides context for investors monitoring valuation metrics, as the spread between intrinsic value and market price remains meaningful. Valuation-focused observers should track whether this gap narrows through price appreciation or shifts in the underlying fundamentals that support the GF Value calculation. - HealthEquity: AI Cash Fears Create A 'Buy' Opportunity (NASDAQ:HQY) (seekingalpha.com, 2026-10-02)
TickrTrends take: HealthEquity operates in the Healthcare sector where artificial intelligence investments can create near-term cash flow pressures that may concern some investors. TickrTrends' current valuation assessment marks the stock as undervalued, suggesting that market concerns about AI-related spending may have created a disconnect between current price and underlying value. Investors focused on valuation metrics should monitor how the company's cash position and capital allocation decisions evolve as AI initiatives mature, since near-term spending concerns could obscure longer-term value creation.
More HQY news
- HQY Maintained by Barclays -- Price Target Raised to $115 (gurufocus.com, 2026-09-18)
- HealthEquity’s (HQY) Health Savings Engine Hits A New Gear (finance.yahoo.com, 2026-09-01)
What people are saying
Follow the HQY conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for HQY in the Healthcare sector showed a shift this week as the Relative Strength Index moved from oversold territory into neutral zone, suggesting a change in momentum dynamics for the stock. The current valuation verdict remains Undervalued based on TickrTrends' analysis.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for HQY show a shift in momentum this week as the RSI zone moved from neutral territory into oversold conditions. The stock's current valuation verdict remains Undervalued based on the analysis. This combination of oversold RSI readings alongside the undervalued assessment may warrant attention from investors monitoring Healthcare sector opportunities.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is HQY stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), HQY is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is HQY's TickrTrends verdict?
HQY's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does HQY compare to other Healthcare stocks?
HQY ranks #10 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is HQY overbought or oversold?
HQY's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does HQY report earnings next?
HQY's next earnings report is scheduled for 2026-12-02, per the published earnings calendar.
Does HQY usually beat earnings estimates?
Over its last 8 reported quarters HQY beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about HQY?
Of 15 analysts covering HQY, 15 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $119 (+29.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
HQY vs ANIP · HQY vs COLL · HQY vs COO · HQY vs DXCM · HQY vs EMBC